Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Discovery of a novel Raf kinase inhibitor.

Lyons JF, Wilhelm S, Hibner B, Bollag G.

Endocr Relat Cancer. 2001 Sep;8(3):219-25. Review.

2.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.

Cancer Res. 2004 Oct 1;64(19):7099-109.

3.

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention.

Herrera R, Sebolt-Leopold JS.

Trends Mol Med. 2002;8(4 Suppl):S27-31. Review. Erratum in: Trends Mol Med 2002 May;8(5):243.

PMID:
11927284
4.

Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP.

Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W.

Nature. 1999 Sep 9;401(6749):173-7.

PMID:
10490027
5.

Ras/Raf signalling and emerging pharmacotherapeutic targets.

Kolch W.

Expert Opin Pharmacother. 2002 Jun;3(6):709-18. Review.

PMID:
12036410
6.

The Ras-Raf-MEK-ERK pathway in the treatment of cancer.

Hilger RA, Scheulen ME, Strumberg D.

Onkologie. 2002 Dec;25(6):511-8. Review.

PMID:
12566895
7.

Inhibition of Raf-1 signaling by a monoclonal antibody, which interferes with Raf-1 activation and with Mek substrate binding.

Kolch W, Philipp A, Mischak H, Dutil EM, Mullen TM, Feramisco JR, Meinkoth JL, Rose DW.

Oncogene. 1996 Sep 19;13(6):1305-14.

PMID:
8808705
8.

Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.

Anders M, Christian C, McMahon M, McCormick F, Korn WM.

Cancer Res. 2003 May 1;63(9):2088-95.

9.

Induction of oocyte maturation by jun-N-terminal kinase (JNK) on the oncogenic ras-p21 pathway is dependent on the raf-MEK signal transduction pathway.

Chie L, Amar S, Kung HF, Lin MC, Chen H, Chung DL, Adler V, Ronai Z, Friedman FK, Robinson RC, Kovac C, Brandt-Rauf PW, Yamaizumi Z, Michl J, Pincus MR.

Cancer Chemother Pharmacol. 2000;45(6):441-9.

PMID:
10854130
10.
11.

Targeting the RAF-MEK-ERK pathway in cancer therapy.

Montagut C, Settleman J.

Cancer Lett. 2009 Oct 8;283(2):125-34. doi: 10.1016/j.canlet.2009.01.022. Epub 2009 Feb 12. Review.

PMID:
19217204
12.

Raf kinase as a target for anticancer therapeutics.

Sridhar SS, Hedley D, Siu LL.

Mol Cancer Ther. 2005 Apr;4(4):677-85. Review.

14.

Raf pathway inhibitors in oncology.

Bollag G, Freeman S, Lyons JF, Post LE.

Curr Opin Investig Drugs. 2003 Dec;4(12):1436-41. Review.

PMID:
14763129
15.

Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.

Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD.

Oncogene. 2000 Sep 28;19(41):4685-94.

16.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Roberts PJ, Der CJ.

Oncogene. 2007 May 14;26(22):3291-310. Review.

PMID:
17496923
17.

MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.

Graham TE, Pfeiffer JR, Lee RJ, Kusewitt DF, Martinez AM, Foutz T, Wilson BS, Oliver JM.

J Immunol. 1998 Dec 15;161(12):6733-44.

18.

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.

Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF.

Recent Prog Horm Res. 2001;56:127-55. Review.

PMID:
11237210
20.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Gollob JA, Wilhelm S, Carter C, Kelley SL.

Semin Oncol. 2006 Aug;33(4):392-406. Review.

PMID:
16890795

Supplemental Content

Support Center